Akeso, Inc. (FRA:4RY)

Market Cap	10.96B +73.1%
Revenue (ttm)	298.43M +34.0%
Net Income	-100.56M
EPS	-0.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	267.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	37
Open	11.80
Previous Close	11.70
Day's Range	11.80 - 11.80
52-Week Range	6.75 - 19.30
Beta	n/a
RSI	38.61
Earnings Date	Mar 15, 2026

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 3,529
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4RY

Financial Performance

Financial numbers in CNY